Abstract
With greater understanding of the molecular biology of cancer, precision oncology therapies are becoming increasingly prevalent. Adverse events associated with these therapies may cause significant harm to patients if not promptly recognized and treated. In this review, we focus on pneumonitis that occurs as a side effect of treatment with precision oncology agents. We discuss the incidence and time to onset of pneumonitis associated with a broad array of precision oncology agents. We highlight the common patterns of pneumonitis and offer a comprehensive approach to evaluation and treatment with therapy-specific guidelines where available.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 26-37 |
| Number of pages | 12 |
| Journal | Journal of Immunotherapy and Precision Oncology |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2018 |
Keywords
- Pneumonitis
- Precision oncology agent
- Pulmonary adverse events
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Immunology
- Immunology and Allergy